GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
- Conditions
- Rhinitis, Allergic, PerennialAllergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 59
- Registration Number
- NCT00848965
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: GSK580299, GSK Biological's HPV vaccine
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1239
- Registration Number
- NCT00849381
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
- Conditions
- Haemophilus InfluenzaeStreptococcus Pneumoniae
- Interventions
- Biological: GSK2231395ABiological: TwinrixTM
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00849069
- Locations
- 🇨🇦
GSK Investigational Site, Halifax, Nova Scotia, Canada
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: placeboBiological: albiglutide uptitrationBiological: albiglutide
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 309
- Registration Number
- NCT00849017
- Locations
- 🇿🇦
GSK Investigational Site, Parow, South Africa
Safety and Efficacy of Albiglutide in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: albiglutideDrug: placebo
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 310
- Registration Number
- NCT00849056
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Food and Relative Bioavailability Study
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00843011
- Locations
- 🇮🇹
GSK Investigational Site, Verona, Veneto, Italy
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1351
- Registration Number
- NCT00843492
- Locations
- 🇪🇸
GSK Investigational Site, Vigo/Pontevedra, Spain
Migraine Study in Adolescent Patients
- Conditions
- Migraine Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 589
- Registration Number
- NCT00843024
- Locations
- 🇺🇸
GSK Investigational Site, Middleton, Wisconsin, United States
Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 198
- Registration Number
- NCT00843193
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Repeat Dose Safety Study for Compound to Treat Anemia
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00840320
- Locations
- 🇦🇺
GSK Investigational Site, Melbourne, Victoria, Australia